Denise Brodey - Profile and Journalist Details

Find journalists that align with your industry, location and vision. Unlock Denise Brodey's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.

Get connected with journalists today
Denise Brodey

Denise Brodey

Verified

Senior Contributor, Forbes

Brookline

Final Covers

Health and Wellness Real Estate RelationshipsParenting and Lifestyle

Doesn’t Cover

Wine and spirits

Journalist Type

-

Seniority Positions

Industries

Medium Formats

Content

Total articles 198

  • Glenmark Recalls Nearly 1.5 Million Bottles of ADHD Drug Atomoxetine

    By Denise Brodey, Oluoma Aneke, Alexis Pellek, Avery Hurt Verified| MedCentral@ About 1.48 million bottles of the generic attention-deficit/hyperactivity disorder (ADHD) drug atomoxetine were recalled from the US market by manufacturer Glenmark Pharmaceuticals after tests found potentially harmful impurities above limits imposed by the US Food and Drug Administration (FDA), according to the FDA. Unacceptable levels of N-nitroso atomoxetine, a potential carcinogen, were found in multiple atomoxetine batches, according to the FDA.

    By Denise Brodey, Oluoma Aneke, Alexis Pellek, Avery Hurt Verified · MedCentral

    Mar. 05, 2025

  • Ann Arbor Area Becomes First Destination in Michigan to Achieve “Destination Verified” Status for Accessible Travel

    By Eliana Satkin, Denise Brodey| travelabilityinsider.com@ Ann Arbor leads the way with Wheel the World’s verification program. Ann Arbor, MI – (November 18, 2024) The greater Ann Arbor area proudly announces its recognition as the first destination in Michigan to achieve the “Destination Verified” status with Wheel the World, a global accessibility platform.

    By Eliana Satkin, Denise Brodey · travelabilityinsider.com Ann Arbor leads the way with Wheel the World’s verification program. Ann Arbor, MI – (November 18, 2024) The greater Ann Arbor area proudly announces its recognition as the first destination in Michigan to achieve the “Destination

    Dec. 05, 2024

  • Glenmark Recalls Nearly 1.5 Million Bottles of ADHD Drug Atomoxetine

    By Denise Brodey, Oluoma Aneke, Alexis Pellek, Avery Hurt Verified| MedCentral@ About 1.48 million bottles of the generic attention-deficit/hyperactivity disorder (ADHD) drug atomoxetine were recalled from the US market by manufacturer Glenmark Pharmaceuticals after tests found potentially harmful impurities above limits imposed by the US Food and Drug Administration (FDA), according to the FDA. Unacceptable levels of N-nitroso atomoxetine, a potential carcinogen, were found in multiple atomoxetine batches, according to the FDA.

    By Denise Brodey, Oluoma Aneke, Alexis Pellek, Avery Hurt Verified · MedCentral

    Mar. 05, 2025

As seen in

Company Info

Forbes

Brookline, United States